Free Trial

Veracyte Q1 2024 Earnings Report

Veracyte logo
$40.89 +1.82 (+4.66%)
(As of 12/20/2024 05:51 PM ET)

Veracyte EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.17
One Year Ago EPS
-$0.11

Veracyte Revenue Results

Actual Revenue
$96.84 million
Expected Revenue
$93.35 million
Beat/Miss
Beat by +$3.49 million
YoY Revenue Growth
+17.50%

Veracyte Announcement Details

Quarter
Q1 2024
Time
After Market Closes

Conference Call Resources

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

Veracyte Earnings Headlines

Veracyte (VCYT) Shares Rebounded in Q3
Did You See Trump’s Bombshell Exec. Order 001?
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
Veracyte: Getting Frothy
See More Veracyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email.

About Veracyte

Veracyte (NASDAQ:VCYT) engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

View Veracyte Profile

More Earnings Resources from MarketBeat

Upcoming Earnings